Skip to content

Preliminary efficacy of a self-guided mobile intervention for reducing stress in depression: A randomized controlled crossover trial.

Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin, Kyu-Man Han, Sang-Won Jeon, Changsu Han

Journal of Affective Disorders June 17, 2026 DOI: 10.1016/j.jad.2026.122143 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled crossover pilot trial Pilot study Peer reviewed
Sample size 39
Population Adults with mild-to-moderate major depressive disorder undergoing pharmacological treatment
Intervention relaxation audio
Duration 4-week intervention
Measures Depression Anxiety Stress Scales-Stress subscale (DASS-Stress)
Topics Depression Meditation
Keywords Humans Treatment outcome Pilot projects Cross-over studies Stress, psychological Adult Middle aged Female Mobile applications Cognitive behavioral therapy Subjective stress Stress reduction Digital health intervention
Key findings The inMind digital intervention was associated with a reduction in DASS-Stress scores (estimate = -2.41), narrowly exceeding the published minimum clinically important difference, with directionally consistent reductions in depressive and anxiety symptoms. The authors report that significant carry-over effects complicated causal interpretation, and that usage metrics showed no significant association with outcomes.

Abstract

Stress worsens clinical outcomes in patients with major depressive disorder (MDD); however, timely accessible stress management tools remain limited. Digital interventions offer scalable adjunctive solutions early during pharmacological treatment. In this multicenter, assessor-blinded, randomized controlled crossover pilot trial, we conducted a preliminary evaluation of the short-term efficacy of a self-guided digital health intervention (inMind) in reducing psychological stress in individuals with mild-to-moderate MDD undergoing pharmacological treatment. We randomly assigned 39 participants to the App-first or Delayed-app sequence, with 36 analyzed. inMind comprised cognitive-behavioral therapy and mindfulness-based stress-reduction modules, relaxation audio, and heart-rate-variability-based stress monitoring. The primary outcome was change in the Depression Anxiety Stress Scales-Stress subscale (DASS-Stress), with secondary measures of depression, anxiety, and perceived stress. Analyses followed a modified intention-to-treat approach using linear mixed-effects models. The inMind condition was associated with a reduction in DASS-Stress (estimate = -2.41; p = 0.047), narrowly exceeding the published minimum clinically important difference, with directionally consistent reductions in depressive and anxiety symptoms. Significant carry-over effects complicated causal interpretation under the no-washout design. Usage metrics showed no significant association with outcomes, consistent with a low-intensity, flexible intervention. Adherence was high in both groups. These preliminary findings suggest that inMind, a 4-week self-guided digital adjunct, may produce modest short-term reductions in stress, depression, and anxiety alongside pharmacotherapy in mild-to-moderate MDD; if confirmed in adequately powered trials, such tools may complement pharmacotherapy and inform future digital adjuncts.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics